{"title":"755 纳米长脉冲亚历山大激光和 2% 盐酸卡替洛尔滴眼液联合治疗较厚表浅婴儿血管瘤的时机和疗效评估","authors":"WeiKang Shi, Lu Jin, AiHua Xu, Yu Gao, Na Zhang","doi":"10.2147/ccid.s483141","DOIUrl":null,"url":null,"abstract":"<strong>Purpose:</strong> Superficial Infantile hemangioma (SIH) is the most common type of IH. Some studies have shown the efficacy of 755-nm long pulse alexandrite laser (LPAL) and topical 2% carteolol hydrochloride (C-HCL) eye drops for the treatment of SIH. This article retrospectively analyzes the safety and efficacy of 755-nm LPAL combined with 2% C-HCL eye drops for treating thicker SIH, and explores the optimal treatment time for SIH.<br/><strong>Materials and Methods:</strong> This study included 2– 5 mm thick SIH patients who received co-treatment of 755-nm LPAL and 2% C-HCL eye drops. The SIH patients were divided into 3 groups based on their age and IH growth curve: ≤ 1 month (≤ 1M), 1– 3 months (excluding 1 month; 1– 3M), and 3– 12 months (excluding 3 months; 3− 12M).<br/><strong>Results:</strong> There was no difference in efficacy between the ≤ 1M and the 1– 3M group, and were both better than the 3– 12M group. Furthermore, there was no difference in the average number of treatments between the ≤ 1M and 1– 3M groups and were both less than the 3– 12M group. There was no significant difference in the incidence of adverse reactions between the groups. Compared with the ≤ 1M and 1– 3M groups, the 3– 12M group indicated more permanent skin lesions after the treatment.<br/><strong>Conclusion:</strong> It was revealed that co-treatment with 755-nm LPAL and 2% C-HCL eye drops is safe and effective against thicker SIH. Compared with the 3– 12M group, ≤ 3 months can achieve better efficacy, requires a shorter treatment time, less likely to leave permanent skin lesions such as scars. Moreover, patients with no proliferation can be observed to 1 month.<br/><br/><strong>Keywords:</strong> infantile hemangioma, 755-nm long pulse alexandrite laser, 2% carteolol hydrochloride eye drops, treatment timing, efficacy<br/>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Timing and Efficacy Evaluation of 755-nm Long Pulse Alexandrite Laser and 2% Carteolol Hydrochloride Eye Drops Co-Treatment for Thicker Superficial Infantile Hemangioma\",\"authors\":\"WeiKang Shi, Lu Jin, AiHua Xu, Yu Gao, Na Zhang\",\"doi\":\"10.2147/ccid.s483141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>Purpose:</strong> Superficial Infantile hemangioma (SIH) is the most common type of IH. Some studies have shown the efficacy of 755-nm long pulse alexandrite laser (LPAL) and topical 2% carteolol hydrochloride (C-HCL) eye drops for the treatment of SIH. This article retrospectively analyzes the safety and efficacy of 755-nm LPAL combined with 2% C-HCL eye drops for treating thicker SIH, and explores the optimal treatment time for SIH.<br/><strong>Materials and Methods:</strong> This study included 2– 5 mm thick SIH patients who received co-treatment of 755-nm LPAL and 2% C-HCL eye drops. The SIH patients were divided into 3 groups based on their age and IH growth curve: ≤ 1 month (≤ 1M), 1– 3 months (excluding 1 month; 1– 3M), and 3– 12 months (excluding 3 months; 3− 12M).<br/><strong>Results:</strong> There was no difference in efficacy between the ≤ 1M and the 1– 3M group, and were both better than the 3– 12M group. Furthermore, there was no difference in the average number of treatments between the ≤ 1M and 1– 3M groups and were both less than the 3– 12M group. There was no significant difference in the incidence of adverse reactions between the groups. Compared with the ≤ 1M and 1– 3M groups, the 3– 12M group indicated more permanent skin lesions after the treatment.<br/><strong>Conclusion:</strong> It was revealed that co-treatment with 755-nm LPAL and 2% C-HCL eye drops is safe and effective against thicker SIH. Compared with the 3– 12M group, ≤ 3 months can achieve better efficacy, requires a shorter treatment time, less likely to leave permanent skin lesions such as scars. Moreover, patients with no proliferation can be observed to 1 month.<br/><br/><strong>Keywords:</strong> infantile hemangioma, 755-nm long pulse alexandrite laser, 2% carteolol hydrochloride eye drops, treatment timing, efficacy<br/>\",\"PeriodicalId\":10447,\"journal\":{\"name\":\"Clinical, Cosmetic and Investigational Dermatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical, Cosmetic and Investigational Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/ccid.s483141\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical, Cosmetic and Investigational Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/ccid.s483141","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Timing and Efficacy Evaluation of 755-nm Long Pulse Alexandrite Laser and 2% Carteolol Hydrochloride Eye Drops Co-Treatment for Thicker Superficial Infantile Hemangioma
Purpose: Superficial Infantile hemangioma (SIH) is the most common type of IH. Some studies have shown the efficacy of 755-nm long pulse alexandrite laser (LPAL) and topical 2% carteolol hydrochloride (C-HCL) eye drops for the treatment of SIH. This article retrospectively analyzes the safety and efficacy of 755-nm LPAL combined with 2% C-HCL eye drops for treating thicker SIH, and explores the optimal treatment time for SIH. Materials and Methods: This study included 2– 5 mm thick SIH patients who received co-treatment of 755-nm LPAL and 2% C-HCL eye drops. The SIH patients were divided into 3 groups based on their age and IH growth curve: ≤ 1 month (≤ 1M), 1– 3 months (excluding 1 month; 1– 3M), and 3– 12 months (excluding 3 months; 3− 12M). Results: There was no difference in efficacy between the ≤ 1M and the 1– 3M group, and were both better than the 3– 12M group. Furthermore, there was no difference in the average number of treatments between the ≤ 1M and 1– 3M groups and were both less than the 3– 12M group. There was no significant difference in the incidence of adverse reactions between the groups. Compared with the ≤ 1M and 1– 3M groups, the 3– 12M group indicated more permanent skin lesions after the treatment. Conclusion: It was revealed that co-treatment with 755-nm LPAL and 2% C-HCL eye drops is safe and effective against thicker SIH. Compared with the 3– 12M group, ≤ 3 months can achieve better efficacy, requires a shorter treatment time, less likely to leave permanent skin lesions such as scars. Moreover, patients with no proliferation can be observed to 1 month.
期刊介绍:
Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. Normal and pathological processes in skin development and aging, their modification and treatment, as well as basic research into histology of dermal and dermal structures that provide clinical insights and potential treatment options are key topics for the journal.
Patient satisfaction, preference, quality of life, compliance, persistence and their role in developing new management options to optimize outcomes for target conditions constitute major areas of interest.
The journal is characterized by the rapid reporting of clinical studies, reviews and original research in skin research and skin care.
All areas of dermatology will be covered; contributions will be welcomed from all clinicians and basic science researchers globally.